Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Stanford University
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00349830
First received: July 5, 2006
Last updated: July 8, 2014
Last verified: July 2014

July 5, 2006
July 8, 2014
January 2002
January 2022   (final data collection date for primary outcome measure)
Survival analysis and response to anti-cancer therapy [ Time Frame: At each follow-up (3 months, 6 months, 1 year; at discretion of MD) 2- Safety Issue?- No ] [ Designated as safety issue: No ]
Survival analysis and response to anti-cancer therapy
Complete list of historical versions of study NCT00349830 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

blood

Non-Probability Sample

cancer patients healthy controls

  • Carcinomas (Including Squamous Cell and Adenocarcinoma)
  • Neoplasms
Procedure: blood draw
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
Not Provided
January 2022   (final data collection date for primary outcome measure)

Inclusion Criteria:- Over age 18, no maximum age limit

  • Prior diagnosis of cancer (unless healthy control)
  • Karnofsky performance status of greater than 70
  • Standard pre-treatment evaluation
  • Negative pregnancy test
  • Signed informed consent

Exclusion Criteria:- Less than 18 years old

- Patient without cancer (unless healthy control)

Both
18 Years and older
Yes
United States
 
NCT00349830
VAR0006, 77923
Not Provided
Stanford University
Stanford University
Not Provided
Principal Investigator: Albert Koong Stanford University
Stanford University
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP